Rheumatic manifestations in inflammatory bowel disease.

Autor: Atzeni F; Rheumatology Unit, L. Sacco University Hospital, Milan, Italy., Defendenti C, Ditto MC, Batticciotto A, Ventura D, Antivalle M, Ardizzone S, Sarzi-Puttini P
Jazyk: angličtina
Zdroj: Autoimmunity reviews [Autoimmun Rev] 2014 Jan; Vol. 13 (1), pp. 20-3. Date of Electronic Publication: 2013 Jun 15.
DOI: 10.1016/j.autrev.2013.06.006
Abstrakt: Musculoskeletal symptoms (articular, periarticular and muscular involvement, osteoporosis and related fractures, and fibromyalgia) are the most common frequent extra-intestinal manifestations of inflammatory bowel disease (IBD) and affect 6-46% of patients. IBD-related arthropathy is one of a group of inflammatory arthritides known as seronegative spondyloarthropathies (SpA), which also includes idiopathic ankylosing spondylitis (AS), reactive arthritis, psoriatic arthritis, and undifferentiated SpA. The articular involvement in IBD significantly affects the patients' quality of the life. Although magnetic resonance imaging (MRI) is still the gold standard for assessing entheseal involvement, ultrasonography (US) is a non-invasive and easily reproducible means of detecting early pathological changes in SpA patients. It can identify characteristic features of SpA such as enthesitis, bone erosions, synovitis, bursitis, and tenosynovitis and is therefore helpful for diagnostic purposes. Anti-TNF drugs should be used to treat AS patients with axial and peripheral symptoms (arthritis and enthesitis) who have persistently high levels of disease activity despite conventional treatment, and adalimumab and infliximab can also be beneficially used in patients with IBD.
(Copyright © 2013 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: